The potential to prevent hyperglycemia-induced RCS and ROS (or RONS) accumulation can presumably be attributed to other oral blood glucose-lowering agents, including sodium-glucose cotransporter 2 (SGLT2) inhibitors [286]. The gene discussed is SLC5A2; the disease is Hyperglycemia.